Director, Clinical Science
Management / Leadership | Research & Development | Research | Leadership | Analytical Skills
Focused on the treatment of cancer patients with precise, controlled and highly active engineered T-cell therapies.
Autolus is a leader in cutting-edge T-cell therapies. Utilising advanced cell programming and manufacturing technologies, we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
Autolus is a privately held biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out and established as an independent company by University College London in 2014.
Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to successfully manufacture, develop and commercialise T-cell therapies.
Autolus is committed to bringing life-changing treatments to cancer patients by reprogramming their own T-cells to more effectively combat the treatment of haematological malignancies and solid tumours.
